Severance Hospital, Yonsei University Health System ( Site 2402)

Seoul 03722

1 studies enrolling now · 1 studies all time

What they study most

Breast Cancer, Breast Neoplasms

Studies at this site

• Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) — Recruiting now